For how we live.
In a 180-infant phase 1/2 trial, a live-attenuated intranasal RSV vaccine raised neutralising antibodies in two-thirds or more of RSV-naive babies but barely budged those already exposed. Sanofi funded the study.
A government-funded test-negative study put effectiveness at 86% against emergency visits and 88% against intensive care, though the smallest subgroups carried wide confidence intervals.
The PROPOSITIS trial put babies on high-flow oxygen face-down or on their backs. Escalation of care was 15% versus 21% — a difference that did not reach significance, and the authors call the study inconclusive.
The SMART trial tested clesrovimab against palivizumab in premature and heart- and lung-affected infants. It was built to show safety, not to prove one prevents more RSV than the other.
A Buenos Aires surveillance cohort estimates 80.8% effectiveness against RSV hospitalisation in infants under three months — close to what the licensing trial found, in a real programme.